Philip J. Barter
Philip J. Barter publishes mostly in Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research, on topics such as Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins and Cancer, Lipids, and Metabolism.
- World rank
- #61,035 of 7,710,434 ranked researchers
- Rank in Australia
- #1,908 of 140,210
- Works
- 545
- Citations
- 54k
- Citations per work
- 98.9
What does Philip J. Barter research?
Philip J. Barter's work is mostly in Medicine (59%), Biochemistry, Genetics and Molecular Biology (17%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences32359.3%
- Medicine32359.3%
- Everything else13023.8%
- Life Sciences9216.9%
- 1Surgery27% of their works
- 2Endocrinology, Diabetes and Metabolism21% of their works
- 3Cancer Research9% of their works
- 4Molecular Biology8% of their works
- 5Cardiology and Cardiovascular Medicine6% of their works
- 6Epidemiology5% of their works
Research topics
- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Cholesterol and Lipid Metabolism
- Peroxisome Proliferator-Activated Receptors
- Adipokines, Inflammation, and Metabolic Diseases
- Atherosclerosis and Cardiovascular Diseases
- Lipid metabolism and biosynthesis
Which keywords describe Philip J. Barter's research?
The keywords of their largest research topics: Cholesterol, Statins, Atherosclerosis, Obesity, Diabetes, C-Reactive Protein, Cardiovascular Disease and Metabolic Syndrome.
- Triacylglycerol Synthesis
- Oxidized LDL
- Adipose Tissue
- Peroxisome Proliferator-Activated Receptors
- SREBP
- Lipid Metabolism
- Inflammation
- Lifestyle Intervention
- Cholesterol-lowering
- Metabolic Syndrome
- C-Reactive Protein
- Obesity
- Statins
- Cholesterol
- Atherosclerosis
- Diabetes
- Cardiovascular Disease
- Cardiovascular Disease Prevention
- Glucose Metabolism
- Metabolism
- Fatty Acid Synthase
- LXR
- PPARs
- Adipokines
- Immune Response
- Lipid Droplets
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 26 words, with their numbers
- Cholesterol4773 topics
- Statins3972 topics
- Atherosclerosis3953 topics
- Obesity3603 topics
- Diabetes3232 topics
- C-Reactive Protein3192 topics
- Cardiovascular Disease3132 topics
- Metabolic Syndrome3132 topics
- Cardiovascular Disease Prevention2821 topic
- Cholesterol-lowering2821 topic
- Glucose Metabolism2761 topic
- Lifestyle Intervention2761 topic
- Metabolism1332 topics
- Inflammation1173 topics
- Fatty Acid Synthase1151 topic
- Lipid Metabolism1151 topic
- LXR861 topic
- SREBP861 topic
- PPARs471 topic
- Peroxisome Proliferator-Activated Receptors471 topic
- Adipokines371 topic
- Adipose Tissue371 topic
- Immune Response331 topic
- Oxidized LDL331 topic
- Lipid Droplets321 topic
- Triacylglycerol Synthesis321 topic
Where does Philip J. Barter work?
Philip J. Barter's main affiliation in the publication record is The Heart Research Institute, Australia.
How many publications and citations does Philip J. Barter have?
OpenAlex counts 545 works and 53,881 citations for Philip J. Barter, an h-index of 101, ranking #61,035 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Philip J. Barter. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.